Healthcare company offers insights into future growth

  • J&J sets guidance for 2024 and longer term
  • Expects 2024 sales to grow 5% to 6%
  • Adjusted EPS to range from $10.55 to $10.75
  • Expects at least 3% operational sales growth in 2025
  • Expects 5% to 7% operational sales compound annual growth rate from 2025 to 2030
  • Medtech segment expects operational sales to be at the upper range of its markets
  • Innovative medicine expected to see 5% to 7% operational sales growth from 2025 to 2030
  • Stock has fallen 10% in the year to date

Johnson & Johnson’s stock was slightly higher premarket Tuesday as the company provided guidance for 2024 and the longer term. The company expects sales to grow 5% to 6% in 2024, with adjusted EPS ranging from $10.55 to $10.75. Despite competition in the U.S. for its plaque psoriasis and psoriatic arthritis treatment, Stelara, J&J anticipates at least 3% operational sales growth in 2025. From 2025 to 2030, the company projects a compound annual growth rate of 5% to 7% for operational sales. Additionally, J&J’s medtech segment expects to perform at the upper range of its markets, which are projected to grow 5% to 7% through 2027. Innovative medicine is also expected to experience 5% to 7% operational sales growth from 2025 to 2030. However, the stock has fallen 10% year to date, while the S&P 500 has gained 19%.

Factuality Level: 8
Factuality Justification: The article provides specific information about Johnson & Johnson’s guidance for 2024 and the longer term, including sales growth and adjusted EPS. It also mentions the recently announced acquisition of Laminar Inc. and its impact on earnings. The article includes some financial data and market expectations. However, it does not provide any analysis or commentary on the accuracy or reliability of the information presented.
Noise Level: 7
Noise Justification: The article provides information about Johnson & Johnson’s stock and its guidance for 2024 and the longer term. However, it lacks in-depth analysis, evidence, and actionable insights. It mainly focuses on financial projections and stock performance without exploring the consequences of decisions or holding powerful people accountable. The article also includes unrelated information about the S&P 500’s performance. Overall, it contains some relevant information but lacks depth and critical analysis.
Financial Relevance: Yes
Financial Markets Impacted: Johnson & Johnson’s stock (JNJ)
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to financial topics as it discusses Johnson & Johnson’s stock performance and provides guidance for future sales and earnings. However, there is no mention of any extreme events or their impact.
Public Companies: Johnson & Johnson (JNJ)
Key People:

Track all markets on TradingView

Reported publicly: www.marketwatch.com www.wsj.com